Context Therapeutics Statistics
Total Valuation
CNTX has a market cap or net worth of $159.00 million. The enterprise value is $148.91 million.
| Market Cap | 159.00M |
| Enterprise Value | 148.91M |
Important Dates
The next estimated earnings date is Wednesday, August 7, 2024, after market close.
| Earnings Date | Aug 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CNTX has 75.00 million shares outstanding.
| Shares Outstanding | 75.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.78% |
| Owned by Institutions (%) | 46.95% |
| Float | 43.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 18.83 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.23, with zero debt.
| Current Ratio | 4.23 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -136.00% and return on invested capital (ROIC) is -264.09%.
| Return on Equity (ROE) | -136.00% |
| Return on Assets (ROA) | -109.50% |
| Return on Capital (ROIC) | -264.09% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.26M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +90.99% in the last 52 weeks. The beta is 2.30, so CNTX's price volatility has been higher than the market average.
| Beta (5Y) | 2.30 |
| 52-Week Price Change | +90.99% |
| 50-Day Moving Average | 1.96 |
| 200-Day Moving Average | 1.36 |
| Relative Strength Index (RSI) | 56.99 |
| Average Volume (20 Days) | 425,369 |
Short Selling Information
The latest short interest is 2.23 million, so 2.97% of the outstanding shares have been sold short.
| Short Interest | 2.23M |
| Short Previous Month | 1.12M |
| Short % of Shares Out | 2.97% |
| Short % of Float | 5.08% |
| Short Ratio (days to cover) | 4.36 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.30M |
| Pretax Income | -21.32M |
| Net Income | -21.32M |
| EBITDA | -21.28M |
| EBIT | -21.32M |
| Earnings Per Share (EPS) | -$1.33 |
Balance Sheet
The company has $10.09 million in cash and no debt, giving a net cash position of $10.09 million or $0.13 per share.
| Cash & Cash Equivalents | 10.09M |
| Total Debt | n/a |
| Net Cash | 10.09M |
| Net Cash Per Share | $0.13 |
| Equity (Book Value) | 8.44M |
| Book Value Per Share | 0.11 |
| Working Capital | 8.43M |
Cash Flow
| Operating Cash Flow | -19.68M |
| Capital Expenditures | n/a |
| Free Cash Flow | -19.68M |
| FCF Per Share | -$1.23 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CNTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -13.41% |
| FCF Yield | -12.38% |
Analyst Forecast
The average price target for CNTX is $6.50, which is 206.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.50 |
| Price Target Difference | 206.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -12.14% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |